RE:RE:Press releaselscfa wrote: Gagnon thinks the NR shows many opportunities ahead for CZO. Long time shareholders see it as a lack of focus and execution in commercializing anything.
I see rare focus. Gilles is a visionary and on the cusp of disrupting major global markets. Right from the start a decade ago Gilles had a vision of building a base business with the two active ingredients and broadening the application of those two ingredients(beta glucan, avenanthramide) into new scientific claims. Dry powder formulations of beta glucan and avenanthramide have been developed allowing CZO to more fully access global markets. New scientific claims for wound healing are beng established and have been called a home run. There's previous work establishing the potential in exercise inflammation for avenanthramide. Other researchers point to the potential of avenanthramide in managing diabetes. The avenanthramide pill has now completed its first two cohorts at multiple the dose of the exercise inflammation study with no adverse events. CZO has now scaled a malting technology that will allow avenanthramide to be sold into the neutraceutical markets. A major company has received sample for testing in food as an anti-microbial. Beta glucan has been validated by another clinical trial for cholesterol applications in a drink form and CZO can go back to that. It has the highest quality oat beta glucan and soon a powder. It also has PGX which can impregnate oat beta glucan with other bioactive. CZO's beta glucan pill appears to help with weight loss which isn't surprising for beta glucan. CZO can go back to the pill later. It has more immediate opportunities. PGX was developed for oat beta glucan and along the way CZO has discovered yeast beta glucan applications of great promise. Bioavailability results with yeast beta glucan blew the competition and oat beta glucan away. PGX is 7 months from the decison point concerning mass industrialization and initial sales at limited volume of an immune booster. Reaching commercial scale for PGX will allow CZO to enter strong partnership and the merger with AEZS could supply the capital and additional human resources. Dr Martin Kolb has said that PGX-YBG could profoundly alter the treatment landscape for fibrosis if preclinical results are replicated and CZO was going ahead with planning as it says it needs a short toxicology study. It seems more of a dotting of i's and crossing of t's than anytihing to satisfy regulators. Toxicology studies have already been favorable and yeast beta glucan is generally accepted as safe in other applications.
Arguably the most important biotech executive in Canada in the last 20 years has validated Gilles business plan and is "thrilled" with the prospects of the merger. The Canadian government has also provided significant funding over time. CZO works with leaders in their fields from Dr. Kolb, to Dr. Ask, to Dr. Hoare, to Dr. Tardif, to Dr. Li, to Natex. World class. PGX development has been guided and informed by discussions with industry as CZO moves from PGX-OBG, to PGX-YBG, etc. Industry giant Symrise has complemented its long-standing product development partnership with CZO.
Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”